James L. Riley - Publications

Affiliations: 
University of Pennsylvania Medical School, Philadelphia, PA, United States 
 1989 Vanderbilt University, Nashville, TN 
 1994 Emory University, Atlanta, GA 

81 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Maldini CR, Gayout K, Leibman RS, Dopkin DL, Mills JP, Shan X, Glover JA, Riley JL. HIV-Resistant and HIV-Specific CAR-Modified CD4 T Cells Mitigate HIV Disease Progression and Confer CD4 T Cell Help In Vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32454027 DOI: 10.1016/j.ymthe.2020.05.012  0.84
2017 Leibman RS, Richardson MW, Ellebrecht CT, Maldini CR, Glover JA, Secreto AJ, Kulikovskaya I, Lacey SF, Akkina SR, Yi Y, Shaheen F, Wang J, Dufendach KA, Holmes MC, Collman RG, ... ... Riley JL, et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. Plos Pathogens. 13: e1006613. PMID 29023549 DOI: 10.1371/journal.ppat.1006613  0.84
2016 Saha A, O'Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, Vincent BG, Tkachev V, Pawlicki JM, Furlan SN, Kean LS, Aoyama K, Taylor PA, Panoskaltsis-Mortari A, Foncea R, ... ... Riley JL, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. The Journal of Clinical Investigation. PMID 27294527 DOI: 10.1172/JCI85796  0.36
2015 Leibman RS, Riley JL. Engineering T Cells to Functionally Cure HIV-1 Infection. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 1149-59. PMID 25896251 DOI: 10.1038/mt.2015.70  0.84
2014 Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4262-73. PMID 24919573 DOI: 10.1158/1078-0432.CCR-13-2627  0.36
2014 Richardson MW, Guo L, Xin F, Yang X, Riley JL. Stabilized human TRIM5α protects human T cells from HIV-1 infection. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1084-95. PMID 24662946 DOI: 10.1038/mt.2014.52  0.36
2014 Zhang Q, Wang HY, Wei F, Liu X, Paterson JC, Roy D, Mihova D, Woetmann A, Ptasznik A, Odum N, Schuster SJ, Marafioti T, Riley JL, Wasik MA. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. Journal of Immunology (Baltimore, Md. : 1950). 192: 2913-9. PMID 24523507 DOI: 10.4049/jimmunol.1302951  0.36
2014 Didigu CA, Wilen CB, Wang J, Duong J, Secreto AJ, Danet-Desnoyers GA, Riley JL, Gregory PD, June CH, Holmes MC, Doms RW. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood. 123: 61-9. PMID 24162716 DOI: 10.1182/blood-2013-08-521229  0.36
2013 Zhang Q, Wei F, Wang HY, Liu X, Roy D, Xiong QB, Jiang S, Medvec A, Danet-Desnoyers G, Watt C, Tomczak E, Kalos M, Riley JL, Wasik MA. The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes. The American Journal of Pathology. 183: 1971-80. PMID 24404580 DOI: 10.1016/j.ajpath.2013.08.030  0.36
2013 Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA, Trotta E, Szot GL, Liu W, Lares A, Lee K, Laing A, Lechler RI, Riley JL, Bluestone JA, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 13: 3010-20. PMID 24102808 DOI: 10.1111/ajt.12433  0.36
2013 Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, ... ... Riley JL, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Science Translational Medicine. 5: 197ra103. PMID 23926201 DOI: 10.1126/scitranslmed.3006034  0.36
2013 Riley JL. Combination checkpoint blockade--taking melanoma immunotherapy to the next level. The New England Journal of Medicine. 369: 187-9. PMID 23724866 DOI: 10.1056/NEJMe1305484  0.36
2013 Wei F, Zhong S, Ma Z, Kong H, Medvec A, Ahmed R, Freeman GJ, Krogsgaard M, Riley JL. Strength of PD-1 signaling differentially affects T-cell effector functions. Proceedings of the National Academy of Sciences of the United States of America. 110: E2480-9. PMID 23610399 DOI: 10.1073/pnas.1305394110  0.36
2013 Huang C, Martin S, Pfleger C, Du J, Buckner JH, Bluestone JA, Riley JL, Ziegler SF. Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28. Journal of Immunology (Baltimore, Md. : 1950). 190: 4470-3. PMID 23543754 DOI: 10.4049/jimmunol.1203561  0.36
2013 Thakral D, Coman MM, Bandyopadhyay A, Martin S, Riley JL, Kavathas PB. The human CD8β M-4 isoform dominant in effector memory T cells has distinct cytoplasmic motifs that confer unique properties. Plos One. 8: e59374. PMID 23533620 DOI: 10.1371/journal.pone.0059374  0.36
2013 Maier DA, Brennan AL, Jiang S, Binder-Scholl GK, Lee G, Plesa G, Zheng Z, Cotte J, Carpenito C, Wood T, Spratt SK, Ando D, Gregory P, Holmes MC, Perez EE, ... Riley JL, et al. Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Human Gene Therapy. 24: 245-58. PMID 23360514 DOI: 10.1089/hum.2012.172  0.36
2012 Richardson MW, Jadlowsky J, Didigu CA, Doms RW, Riley JL. Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. Journal of Immunology (Baltimore, Md. : 1950). 189: 3815-21. PMID 22988032 DOI: 10.4049/jimmunol.1201431  0.36
2012 Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Science Translational Medicine. 4: 134ra62. PMID 22593175 DOI: 10.1126/scitranslmed.3003330  0.36
2012 Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science Translational Medicine. 4: 132ra53. PMID 22553251 DOI: 10.1126/scitranslmed.3003761  0.36
2012 Plesa G, Zheng L, Medvec A, Wilson CB, Robles-Oteiza C, Liddy N, Bennett AD, Gavarret J, Vuidepot A, Zhao Y, Blazar BR, Jakobsen BK, Riley JL. TCR affinity and specificity requirements for human regulatory T-cell function. Blood. 119: 3420-30. PMID 22318202 DOI: 10.1182/blood-2011-09-377051  0.36
2011 Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, Levine BL, June CH, Medin JA, Fowler DH. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Science Translational Medicine. 3: 111ra120. PMID 22133721 DOI: 10.1126/scitranslmed.3003130  0.36
2011 Youngblood B, Oestreich KJ, Ha SJ, Duraiswamy J, Akondy RS, West EE, Wei Z, Lu P, Austin JW, Riley JL, Boss JM, Ahmed R. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity. 35: 400-12. PMID 21943489 DOI: 10.1016/j.immuni.2011.06.015  0.36
2011 Beyer M, Thabet Y, Müller RU, Sadlon T, Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, Schönfeld EA, Böttcher J, Golovina T, Mayer CT, Hofmann A, ... ... Riley JL, et al. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nature Immunology. 12: 898-907. PMID 21841785 DOI: 10.1038/ni.2084  0.36
2011 Ye Q, Loisiou M, Levine BL, Suhoski MM, Riley JL, June CH, Coukos G, Powell DJ. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. Journal of Translational Medicine. 9: 131. PMID 21827675 DOI: 10.1186/1479-5876-9-131  0.36
2011 Hippen KL, Riley JL, June CH, Blazar BR. Clinical perspectives for regulatory T cells in transplantation tolerance. Seminars in Immunology. 23: 462-8. PMID 21820917 DOI: 10.1016/j.smim.2011.07.008  0.36
2011 Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4719-30. PMID 21610146 DOI: 10.1158/1078-0432.CCR-11-0351  0.36
2011 Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, June CH, Scheinberg P, Douek DC, Miller JS, Wagner JE, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Science Translational Medicine. 3: 83ra41. PMID 21593401 DOI: 10.1126/scitranslmed.3001809  0.36
2011 Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, Riley JL, June CH, Miller JS, Wagner JE, Blazar BR. Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 11: 1148-57. PMID 21564534 DOI: 10.1111/j.1600-6143.2011.03558.x  0.36
2011 Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, Rebar EJ, Sherrill-Mix SA, Patro SC, Secreto AJ, Jordan AP, Lee G, Kahn J, Aye PP, Bunnell BA, Lackner AA, ... ... Riley JL, et al. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. Plos Pathogens. 7: e1002020. PMID 21533216 DOI: 10.1371/journal.ppat.1002020  0.36
2010 Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, Carroll RG, Riley JL, June CH. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Science Translational Medicine. 2: 55ra78. PMID 20980695 DOI: 10.1126/scitranslmed.3000448  0.36
2010 Amarnath S, Costanzo CM, Mariotti J, Ullman JL, Telford WG, Kapoor V, Riley JL, Levine BL, June CH, Fong T, Warner NL, Fowler DH. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. Plos Biology. 8: e1000302. PMID 20126379 DOI: 10.1371/journal.pbio.1000302  0.36
2010 Mukherjee R, Plesa G, Sherrill-Mix S, Richardson MW, Riley JL, Bushman FD. HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse model. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 803-11. PMID 20104212 DOI: 10.1038/mt.2009.316  0.36
2009 June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nature Reviews. Immunology. 9: 704-16. PMID 19859065 DOI: 10.1038/nri2635  0.36
2009 Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 30: 656-65. PMID 19464988 DOI: 10.1016/j.immuni.2009.04.006  0.36
2009 Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1453-64. PMID 19384291 DOI: 10.1038/mt.2009.83  0.36
2009 Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the United States of America. 106: 3360-5. PMID 19211796 DOI: 10.1073/pnas.0813101106  0.36
2008 Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, Milicic A, Mahon T, Sutton DH, Laugel B, Moysey R, Cameron BJ, Vuidepot A, Purbhoo MA, Cole DK, ... ... Riley JL, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nature Medicine. 14: 1390-5. PMID 18997777 DOI: 10.1038/nm.1779  0.36
2008 Paulos CM, Suhoski MM, Plesa G, Jiang T, Basu S, Golovina TN, Jiang S, Aqui NA, Powell DJ, Levine BL, Carroll RG, Riley JL, June CH. Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunologic Research. 42: 182-96. PMID 18949448 DOI: 10.1007/s12026-008-8070-9  0.36
2008 Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M, Scholler J, Hao X, Mexas A, Carroll RG, June CH, Riley JL. Genetic engineering of T cells for adoptive immunotherapy. Immunologic Research. 42: 166-81. PMID 18841331 DOI: 10.1007/s12026-008-8057-6  0.36
2008 Carroll RG, Carpenito C, Shan X, Danet-Desnoyers G, Liu R, Jiang S, Albelda SM, Golovina T, Coukos G, Riley JL, Jonak ZL, June CH. Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. Plos One. 3: e3289. PMID 18818761 DOI: 10.1371/journal.pone.0003289  0.36
2008 Richardson MW, Carroll RG, Stremlau M, Korokhov N, Humeau LM, Silvestri G, Sodroski J, Riley JL. Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. Journal of Virology. 82: 11117-28. PMID 18768965 DOI: 10.1128/JVI.01046-08  0.36
2008 Golovina TN, Mikheeva T, Suhoski MM, Aqui NA, Tai VC, Shan X, Liu R, Balcarcel RR, Fisher N, Levine BL, Carroll RG, Warner N, Blazar BR, June CH, Riley JL. CD28 costimulation is essential for human T regulatory expansion and function. Journal of Immunology (Baltimore, Md. : 1950). 181: 2855-68. PMID 18684977  0.36
2008 Hippen KL, Harker-Murray P, Porter SB, Merkel SC, Londer A, Taylor DK, Bina M, Panoskaltsis-Mortari A, Rubinstein P, Van Rooijen N, Golovina TN, Suhoski MM, Miller JS, Wagner JE, June CH, ... Riley JL, et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood. 112: 2847-57. PMID 18645038 DOI: 10.1182/blood-2008-01-132951  0.36
2008 Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, ... ... Riley JL, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nature Biotechnology. 26: 808-16. PMID 18587387 DOI: 10.1038/nbt1410  0.36
2008 Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. Journal of Immunology (Baltimore, Md. : 1950). 180: 5794-8. PMID 18424697  0.36
2007 Plesa G, Dai J, Baytop C, Riley JL, June CH, O'Doherty U. Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. Journal of Virology. 81: 13938-42. PMID 17928354 DOI: 10.1128/JVI.01745-07  0.36
2007 Hexner EO, Danet-Desnoyers GA, Zhang Y, Frank DM, Riley JL, Levine BL, Porter DL, June CH, Emerson SG. Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 1135-44. PMID 17889349 DOI: 10.1016/j.bbmt.2007.06.010  0.36
2007 Chemnitz JM, Eggle D, Driesen J, Classen S, Riley JL, Debey-Pascher S, Beyer M, Popov A, Zander T, Schultze JL. RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma. Blood. 110: 3226-33. PMID 17644739 DOI: 10.1182/blood-2006-12-064360  0.36
2007 Li B, Samanta A, Song X, Iacono KT, Brennan P, Chatila TA, Roncador G, Banham AH, Riley JL, Wang Q, Shen Y, Saouaf SJ, Greene MI. FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. International Immunology. 19: 825-35. PMID 17586580 DOI: 10.1093/intimm/dxm043  0.36
2007 Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, Carroll RG, Riley JL, June CH. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 981-8. PMID 17375070 DOI: 10.1038/mt.sj.6300134  0.36
2007 Li B, Samanta A, Song X, Iacono KT, Bembas K, Tao R, Basu S, Riley JL, Hancock WW, Shen Y, Saouaf SJ, Greene MI. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proceedings of the National Academy of Sciences of the United States of America. 104: 4571-6. PMID 17360565 DOI: 10.1073/pnas.0700298104  0.36
2007 Riley JL, June CH. The road to recovery: translating PD-1 biology into clinical benefit. Trends in Immunology. 28: 48-50. PMID 17188572 DOI: 10.1016/j.it.2006.12.001  0.36
2007 Riley JL, June CH. Genetically Modified T Cells for Human Gene Therapy Concepts in Genetic Medicine. 193-205. DOI: 10.1002/9780470184585.ch16  0.36
2006 Chemnitz JM, Driesen J, Classen S, Riley JL, Debey S, Beyer M, Popov A, Zander T, Schultze JL. Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Research. 66: 1114-22. PMID 16424048 DOI: 10.1158/0008-5472.CAN-05-3252  0.36
2006 Hu S, Du MQ, Park SM, Alcivar A, Qu L, Gupta S, Tang J, Baens M, Ye H, Lee TH, Marynen P, Riley JL, Yang X. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. The Journal of Clinical Investigation. 116: 174-81. PMID 16395405 DOI: 10.1172/JCI25641  0.36
2005 Kovacs B, Parry RV, Ma Z, Fan E, Shivers DK, Freiberg BA, Thomas AK, Rutherford R, Rumbley CA, Riley JL, Finkel TH. Ligation of CD28 by its natural ligand CD86 in the absence of TCR stimulation induces lipid raft polarization in human CD4 T cells. Journal of Immunology (Baltimore, Md. : 1950). 175: 7848-54. PMID 16339520  0.36
2005 Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Molecular and Cellular Biology. 25: 9543-53. PMID 16227604 DOI: 10.1128/MCB.25.21.9543-9553.2005  0.36
2005 Perez EE, Riley JL, Carroll RG, von Laer D, June CH. Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. Clinical Immunology (Orlando, Fla.). 115: 26-32. PMID 15870017 DOI: 10.1016/j.clim.2005.02.019  0.36
2005 Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood. 105: 13-21. PMID 15353480 DOI: 10.1182/blood-2004-04-1596  0.36
2004 Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. Journal of Immunology (Baltimore, Md. : 1950). 173: 945-54. PMID 15240681  0.36
2004 Bauer DE, Harris MH, Plas DR, Lum JJ, Hammerman PS, Rathmell JC, Riley JL, Thompson CB. Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 18: 1303-5. PMID 15180958 DOI: 10.1096/fj.03-1001fje  0.36
2004 Maus MV, Kovacs B, Kwok WW, Nepom GT, Schlienger K, Riley JL, Allman D, Finkel TH, June CH. Extensive replicative capacity of human central memory T cells. Journal of Immunology (Baltimore, Md. : 1950). 172: 6675-83. PMID 15153483  0.36
2003 Simmons G, Rennekamp AJ, Chai N, Vandenberghe LH, Riley JL, Bates P. Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection. Journal of Virology. 77: 13433-8. PMID 14645601 DOI: 10.1128/JVI.77.24.13433-13438.2003  0.36
2003 Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 171: 166-74. PMID 12816995  0.36
2003 Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1517-27. PMID 12684428  0.36
2003 Maus MV, Riley JL, Kwok WW, Nepom GT, June CH. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clinical Immunology (Orlando, Fla.). 106: 16-22. PMID 12584046 DOI: 10.1016/S1521-6616(02)00017-7  0.36
2003 Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, Whitbeck JC, Burke E, Buchmeier MJ, Soilleux EJ, Riley JL, Doms RW, Bates P, Pöhlmann S. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology. 305: 115-23. PMID 12504546 DOI: 10.1006/viro.2002.1730  0.36
2002 Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clinical Immunology (Orlando, Fla.). 105: 259-72. PMID 12498807 DOI: 10.1006/clim.2002.5277  0.36
2002 Kovacs B, Maus MV, Riley JL, Derimanov GS, Koretzky GA, June CH, Finkel TH. Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation. Proceedings of the National Academy of Sciences of the United States of America. 99: 15006-11. PMID 12419850 DOI: 10.1073/pnas.232058599  0.36
2002 Riley JL, Mao M, Kobayashi S, Biery M, Burchard J, Cavet G, Gregson BP, June CH, Linsley PS. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proceedings of the National Academy of Sciences of the United States of America. 99: 11790-5. PMID 12195015 DOI: 10.1073/pnas.162359999  0.36
2002 Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, Elstrom RL, June CH, Thompson CB. The CD28 signaling pathway regulates glucose metabolism. Immunity. 16: 769-77. PMID 12121659 DOI: 10.1016/S1074-7613(02)00323-0  0.36
2002 Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation Journal of Immunology. 168: 4272-4276. PMID 11970966  0.36
2002 Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nature Biotechnology. 20: 143-8. PMID 11821859 DOI: 10.1038/nbt0202-143  0.36
1999 Xiao X, Wu L, Stantchev TS, Feng YR, Ugolini S, Chen H, Shen Z, Riley JL, Broder CC, Sattentau QJ, Dimitrov DS. Constitutive cell surface association between CD4 and CCR5 Proceedings of the National Academy of Sciences of the United States of America. 96: 7496-7501. PMID 10377443 DOI: 10.1073/pnas.96.13.7496  0.36
1998 Morris AC, Riley JL, Fleming WH, Boss JM. MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression. American Journal of Reproductive Immunology (New York, N.Y. : 1989). 40: 385-94. PMID 9894561 DOI: 10.1111/j.1600-0897.1998.tb00423.x  0.36
1998 Levine BL, Cotte J, Small CC, Carroll RG, Riley JL, Bernstein WB, Van Epps DE, Hardwick RA, June CH. Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. Journal of Hematotherapy. 7: 437-48. PMID 9829318 DOI: 10.1089/scd.1.1998.7.437  0.36
1998 Yang LP, Riley JL, Carroll RG, June CH, Hoxie J, Patterson BK, Ohshima Y, Hodes RJ, Delespesse G. Productive infection of neonatal CD8+ T lymphocytes by HIV-1 Journal of Experimental Medicine. 187: 1139-1144. PMID 9529330 DOI: 10.1084/jem.187.7.1139  0.36
1996 Levine BL, Mosca JD, Riley JL, Carroll RG, Vahey MT, Jagodzinski LL, Wagner KF, Mayers DL, Burke DS, Weislow OS, St Louis DC, June CH. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science (New York, N.Y.). 272: 1939-43. PMID 8658167 DOI: 10.1126/science.272.5270.1939  0.36
1995 Riley JL, Westerheide SD, Price JA, Brown JA, Boss JM. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA) Immunity. 2: 533-543. PMID 7749984 DOI: 10.1016/1074-7613(95)90033-0  0.36
1995 Lu HT, Riley JL, Babcock GT, Huston M, Stark GR, Boss JM, Ransohoff RM. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. The Journal of Experimental Medicine. 182: 1517-25. PMID 7595221 DOI: 10.1084/jem.182.5.1517  0.36
1994 Chin KC, Mao C, Skinner C, Riley JL, Wright KL, Moreno CS, Stark GR, Boss JM, Ting JP. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity. 1: 687-97. PMID 7600294 DOI: 10.1016/1074-7613(94)90039-6  0.36
Show low-probability matches.